Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus vs Mycophenolic Acid in De Novo Renal Transplant Recipients
NCT00251004Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2005
- Primary completion
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of everolimus in kidney transplant rejection, sponsored by Novartis. Started Oct 2005; status: completed.
02
Drugs
everolimus
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00251004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00251004.